GaffenS.L., KramerJ.M., YuJ.J., ShenF.: The IL-17 cytokine family. Vitam Horm, 74: 255–282, 2006.
2.
BeerepootL.V., MehraN., VermmatJ.S.P., ZonnbenbergB.A., GebbinkMFGB, VoestE.E.: Increased levels of viable circulating endothelial cells are an indicator of progressive disease in cancer patients. Ann Oncol, 15: 139–145, 2004.
3.
PelosiE., ValtieriM., CoppolaS., BottaR., GabbianelliM., LulliV.: Identification of the hemangioblast in postnatal life. Blood, 100: 3203–3208, 2002.
4.
CireeA., MichelL., Camilleri-BroetS., Jean LousF., OsterM., FlageulB., SenetP., FossiezF., FridmanW.H., BachelezH., TartourE.: Expression and activity of IL-17 in cutaneous T cell lymphomas (mycosis fungoides and Sezary syndrome). Int J Cancer, 112: 113–120, 2004.
5.
StarnesT., RobertsonM.J., SledgeG., KelichS., NakshatriH., BroxmeyerH.E., HromasR.: IL-17F, a novel cytokine selectively expressed in activated T cells and monocytes, regulates angiogenesis and endothelial cell cytokine production. J Immunol, 167: 4137–4140, 2001.
6.
NumasakiM., TomiokaY., TakahashiH., SasakiH.: IL-17 and IL-17F modulate GM-CSF production by lung microvascular endothelial cells stimulated with IL-1 alpha and/or TNF-alpha. Immunol Lett, 95: 175–184, 2004.
AleksandrakisM.G., PappaC.A., MiyakisS., SfiridakiA., KafousiM., AlegakisA., StathopoulosE.N.: Serum interleukin-17 and its relationship to angiogenic factors in multiple myeloma. Eur J Int Med, 17: 412–416, 2006.
9.
TartourE., FossiezF., JoyeuxI., GalinhaA., GeyA., ClaretE., Sastre-GarauX., CouturierJ., MosseriV., VivesV.: Interleukin 17, a T-cell-derived cytokine, promotes tumorigenicity of human cervical tumors in nude mice. Cancer Res, 59: 3698–3704, 1999.
10.
BenchetritF., CireeA., VivesV., WarnierG., GeyA., Sautes-FridmanC., FossiezF., HaicheurN., FridmanW.H., TartourE.: Interleukin-17 inhibits tumor cell growth by means of a T-cell-dependent mechanism. Blood, 99: 2114–2121, 2002.
11.
ZhouL., PengS., DuanJ., ZhouJ., WangL., WangJ.: A human B cell line AF10 expressing HIL-17. Biochem Mol Biol Int, 45: 1113–1119, 1998.
NumasakiM., TomiokaY., TakahashiH., SasakiH.: IL-17 and IL-17F modulate GM-CSF production by lung microvascular endothelial cells stimulated with IL-1beta and/or TNF-alpha. Immunol Lett, 95: 175–184, 2004.
14.
DaiC.H., KrantzS.B., DessyprisE.N., MeensR.T.Jr., HornS.T., GilbertH.J.: Polycythemia vera. II. Hypersensitivity of bone marrow erythroid, granulocyte-macrophage, and megakaryocyte progenitor cells to interleukin-3 and granulocyte-macrophage colony-stimulating factor. Blood, 80: 891–899, 2002.
15.
JovcicG., BugarskiD., PatakovM., KrsticA., VlaskiM., StojanovicN., MilenkovicP.: In vivo effects of interleukin-17 on haematopoietic cells and cytokine release in normal mice. Cell Prolif, 37: 401–412, 2004.
16.
StarnesT., BroxmeyerH.E., RobertsonM.J., HronasR.: Cutting edge: IL-17 a novel member of the IL-17 family, stimulates cytokine production and inhibits hemopoiesis. J Immunol, 169: 642–646, 2002.
17.
BoveriE., PassamontiF., UmiE., PietraD., ElenaC., ArcainiL., PascuttoC., CastelloA., CazzolaM., MagriniV., LazzarinoM.: Bone marrow microvessel density in chronic myeloproliferative disorders. A study of 115 patients with clinicopathological and molecular correlations. Br J Haematol, 140: 162–168, 2008.
18.
PanteliK., BaiM., HstzmichaelE., ZagorianakovN., AgnantisN.J., BourantesK.: Serum levels and bone marrow immunohistochemical expression of vascular endothelial growth factor in patients with chronic myeloproliferative diseases. Haematology, 1: 155–158, 2007.
